GSK appoints Hans Wijers to its Board as a Non-Executive Director
24 January 2013 | By GlaxoSmithKline
GlaxoSmithKline announced the appointment of Hans Wijers to its Board as a Non-Executive Director, effective 1st April 2013...
List view / Grid view
News
Gilead initiates Phase 3 clinical program for tenofovir alafenamide
24 January 2013 | By Gilead Sciences
“We are pleased to move TAF into Phase 3 clinical research...”
Biogen Idec announces positive top-line results from Phase 3 study of peginterferon beta-1a in multiple sclerosis
24 January 2013 | By Biogen Idec
Biogen Idec released the primary efficacy analysis and safety data from its Phase 3 pivotal clinical trial...
Novartis drug Exjade® first treatment approved by FDA
23 January 2013 | By Novartis
Novartis drug Exjade® first treatment approved by FDA for chronic iron overload in patients with non-transfusion-dependent thalassemia...
Recent advances in Microbiology – Rapid Mycoplasma Test
22 January 2013 | By SMi Group
SMi’s Pharmaceutical Microbiology conference taking place on the 30th & 31st January London...
ABRAXANE® (nab-paclitaxel) plus gemcitabine demonstrates survival advantage in Phase III study of patients with advanced pancreatic cancer1
22 January 2013 | By Weber Shandwick
Celgene UK and Ireland announced that its phase III clinical trial of ABRAXANE® (nab-paclitaxel) in combination with gemcitabine in treatment-naïve patients with metastatic pancreatic cancer demonstrated a statistically significant improvement in overall survival...
Automated buffy coat isolation on Tecan’s Freedom EVO®
22 January 2013 | By kdm communications
Tecan and IBBL have co-developed an automated platform for buffy coat extraction based on a Freedom EVO® 200 workstation...
Pfizer partnership organizations significantly benefit from Pfizer’s Global Health Fellows Program
22 January 2013 | By Pfizer
Pfizer celebrates 10th anniversary of this signature social investment program...
Novartis receives EU approval for Bexsero®
22 January 2013 | By Novartis
Bexsero®, first vaccine to prevent the leading cause of life-threatening meningitis across Europe...
GSK signs up to UK Government’s Public Health Responsibility Deal
22 January 2013 | By GlaxoSmithKline
As a global healthcare company, at GSK we believe we have a responsibility to help people make healthier choices...
Tresiba® and Ryzodeg® receive marketing authorisations in Europe
21 January 2013 | By Novo Nordisk
“We look forward to making Tresiba® and Ryzodeg® available to many people with diabetes in Europe”
Pfizer’s Bosutinib receives positive opinion
18 January 2013 | By Pfizer
“We are very pleased with this positive recommendation on bosutinib by the CHMP..."
Novartis receives positive CHMP opinion for Ilaris®
18 January 2013 | By Novartis
"Novartis welcomes the decision by the CHMP in support of the approval of Ilaris in the EU"
Jetrea(TM) receives positive CHMP opinion
18 January 2013 | By Novartis
Jetrea(TM) would become the first drug to treat sight-threatening vitreomacular traction and macular hole...
Hyglos extends its endotoxin detection portfolio and introduces EndoZyme® – enhanced recombinant Factor C (rFC) Assay
Hyglos has announced the commercial launch of EndoZyme®, a homogeneous fluorescence microplate assay using recombinant Factor C derived from horseshoe crab, for measuring endotoxin (Lipopolysaccharides, LPS) in pharmaceuticals, biologics and medical equipment.
